ACTC Stem Cell Trials to Enroll Patients With Better Vision

- Breaking News Related to Macular Degeneration, Cataract, Glaucoma, Corneal Disease and Other Eye Conditions - http://eyedocnews.com -

ACTC to Enroll Patients With Better Vision in Stem Cell Trials

Posted By Dr. Ari Weitzner On February 5, 2013 @ 5:06 am In Clinical Trials,Macular Degeneration,Research,Stem Cell Therapies | Comments Disabled

In late January, Advanced Cell Technology, Inc. (OTCBB: ACTC) announced that it is amending the patient treatment protocol to enroll patients with better vision for the remainder of its Phase I clinical stem cell trials for Stargardt’s macular dystrophy (SMD) and dry age-related macular degeneration (dry AMD) currently being conducted in the U.S. and Europe. As such, patients with a visual acuity of 20/100 will be eligible for enrollment in the remainder of the trials (whereas previously, only patients with a visual acuity of 20/400 were eligible to participate).

By treating patients at an earlier stage of SMD and dry AMD disease, ACTC believes that treatment can have a more significant positive impact on patients’ photoreceptor rescue and visual function.

Click here ^[1] to read the full press release.

Article printed from Breaking News Related to Macular Degeneration, Cataract, Glaucoma, Corneal Disease and Other Eye Conditions: http://eyedocnews.com

URL to article: http://eyedocnews.com/007010-actc-to-enroll-patients-with-better-vision-in-stem-cell-trials/

URLs in this post:

[1] Click here: http://www.advancedcell.com/news-and-media/press-releases/patients-with-better-vision-to-be-enrolled-in-act-s-clinical-trials-for-macular-degeneration/index.asp

Click here to print.